CL2023001367A1 - Inhibidores de btk - Google Patents

Inhibidores de btk

Info

Publication number
CL2023001367A1
CL2023001367A1 CL2023001367A CL2023001367A CL2023001367A1 CL 2023001367 A1 CL2023001367 A1 CL 2023001367A1 CL 2023001367 A CL2023001367 A CL 2023001367A CL 2023001367 A CL2023001367 A CL 2023001367A CL 2023001367 A1 CL2023001367 A1 CL 2023001367A1
Authority
CL
Chile
Prior art keywords
btk inhibitors
formula
btk
inhibitors
variables
Prior art date
Application number
CL2023001367A
Other languages
English (en)
Inventor
Bin Ma
Robin Prince
Martin Himmelbauer
Brian T Hopkins
Isaac Marx
Jurgen Schulz
George Vandeveer
Marta Nevalainen
Teyu Chen
Zain Yousaf
Vatee Pattaropong
John Howard Jones
Edward Yin-Shiang Lin
Lopez De Turiso Felix Gonzales
Thomas Purgett
Andrew George Capacci
Simone Sciabola
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of CL2023001367A1 publication Critical patent/CL2023001367A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Provided are compounds of Formula (I’), or pharmaceutically acceptable salts thereof, wherein the variables in the formula are as as defined herein; and methods for their use and production.
CL2023001367A 2020-11-13 2023-05-11 Inhibidores de btk CL2023001367A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063113515P 2020-11-13 2020-11-13

Publications (1)

Publication Number Publication Date
CL2023001367A1 true CL2023001367A1 (es) 2024-01-05

Family

ID=78828007

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001367A CL2023001367A1 (es) 2020-11-13 2023-05-11 Inhibidores de btk

Country Status (14)

Country Link
US (1) US20240083900A1 (es)
EP (1) EP4244223A1 (es)
JP (1) JP2023549360A (es)
KR (1) KR20230119134A (es)
CN (1) CN116783199A (es)
AR (1) AR124048A1 (es)
AU (1) AU2021377891A1 (es)
BR (1) BR112023009116A2 (es)
CL (1) CL2023001367A1 (es)
CO (1) CO2023007677A2 (es)
MX (1) MX2023005626A (es)
TW (1) TW202233624A (es)
UY (1) UY39517A (es)
WO (1) WO2022104079A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086575A1 (en) * 2021-11-12 2023-05-19 Biogen Ma Inc. Btk inhibitors
WO2023220049A1 (en) * 2022-05-10 2023-11-16 Biogen Ma Inc. Crystalline polymorphs of n-methyl-n-((1s,3s)-3-methyl-3-((6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)acrylamide
WO2024083111A1 (zh) * 2022-10-18 2024-04-25 首药控股(北京)股份有限公司 一种新型杂环化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013055645A1 (en) * 2011-10-12 2013-04-18 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
LT3049417T (lt) * 2013-07-31 2019-02-11 Merck Patent Gmbh Piridinai, pirimidnai ir pirazinai kaip btk inhibitoriai ir jų panaudojimas
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
EP3891149A4 (en) * 2018-12-07 2022-09-07 Sunshine Lake Pharma Co., Ltd. RET INHIBITOR, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Also Published As

Publication number Publication date
BR112023009116A2 (pt) 2023-10-03
CN116783199A (zh) 2023-09-19
AR124048A1 (es) 2023-02-08
MX2023005626A (es) 2023-07-31
AU2021377891A9 (en) 2024-04-18
EP4244223A1 (en) 2023-09-20
KR20230119134A (ko) 2023-08-16
CO2023007677A2 (es) 2023-09-08
US20240083900A1 (en) 2024-03-14
TW202233624A (zh) 2022-09-01
AU2021377891A1 (en) 2023-07-06
WO2022104079A1 (en) 2022-05-19
UY39517A (es) 2022-06-30
JP2023549360A (ja) 2023-11-24

Similar Documents

Publication Publication Date Title
CL2023001367A1 (es) Inhibidores de btk
CY1123186T1 (el) Μακροκυκλικοι mcl1 αναστολεις για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1124837T1 (el) Ενωσεις βενζο[β]θειοφαινιου ως αγωνιστες sting
JOP20220142A1 (ar) مثبطات kras g12c
MX2020013014A (es) N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
CO2022006858A2 (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
CR20210608A (es) Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
MD3497103T2 (ro) Inhibitori de piridopirimidinonă CDK2/4/6
CY1118993T1 (el) Υποκατεστημενες ενωσεις τετραϋδροϊσοκινολινης ως αναστολεις τελεστη xiα
ECSP21091615A (es) Derivados de benzisoxazol sulfonamida
BRPI0412999A (pt) 2-aminotetralina substituìda para tratamento de depressão
MX2020010181A (es) Compuestos de piperidina como inhibidores covalentes de menina.
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
UY28255A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del veger
CY1109085T1 (el) Νεα αλατα
ECSP099046A (es) Derivados ciclopropil amina
WO2021079196A3 (en) Mettl3 modulators
MX2023007287A (es) N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas.
CY1126039T1 (el) Ενωσεις και συνθεσεις ουριας ως αναστολεις της ατρ-ασης smarca2/brm
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
CR20210364A (es) Compuestos de quinolina como inhibidores de quinasas tam y met
MX2023003183A (es) Compuestos heterociclicos de heteroarilo y usos de los mismos.